Developing new treatments for tuberculosis

Know More
 

Fighting TB, a disease that kills more than 1.5 million people every year

Know More
 

A single product, multiple indications

Know More
 

A GMP Plant to offer specialized services to biotech industry

KNOW MORE

Archivel Farma is a R&D biotech company that develops immunotherapeutic agents to respond to unmet medical needs

Tuberculosis (TB) is the greatest killer worldwide due to a single infectious agent

One third of the world’s population is infected with Mycobacterium tuberculosis

RUTI® is the most promising therapeutic vaccine against TB out of 12 in development

One million children worldwide fell ill with tuberculosis in 2016

Mismanagement of treatment can produce multidrug-resistant TB

RUTI® is being evaluated to treat diseases such as asthma and allergic rhinitis

News

ArchivelPress releaseResearch
08/04/2020

Archivel Farma’s RUTI® vaccine to start a clinical trial to increase the immunity of healthcare professionals exposed to the risk of COVID-19

The clinical trial will be carried out at the Germans Trias i Pujol Hospital in Badalona (Can RUTI), and it will include 300 healthy health professionals in direct contact with…
Albert Canals
2
General
05/11/2019

Extension of the authorization for the manufacture of medicines

As of 30th October 2019, Archivel Farma has obtained from the Spanish Health Authority the authorization as Manufacturer for Sterile investigational medicinal products for terminal sterilised operations of Solids and Implants…
Albert Canals
0
Research
20/02/2019

Archivel Farma at the annual TBVI meeting

On January 29, Archivel Farma, represented by its CEO, Olga Rúe, and Dr. Pere Joan Cardona, scientific advisor to the company, participated in the annual meeting of the Tuberculosis Vaccine…
Adela Farré
0